China Biologic Products 10-Q 5 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 05, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	China Biologic Products, Inc.
Entity Central Index Key	1,369,868
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	CBPO
Entity Common Stock, Shares Outstanding		25,708,001

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 106,614,708	$ 80,820,224
Restricted cash deposits		$ 63,677,610
Time deposits	$ 72,226,607
Accounts receivable, net of allowance for doubtful accounts	38,328,831	$ 19,402,820
Inventories	127,039,477	101,304,932
Prepayments and other current assets, net of allowance for doubtful accounts	27,789,090	14,781,658
Total Current Assets	371,998,713	279,987,244
Property, plant and equipment, net	91,208,433	80,230,888
Land use rights, net	15,837,832	11,909,136
Deposits related to land use rights	$ 12,822,069	12,792,355
Restricted cash and cash deposits, excluding current portion		40,230,250
Equity method investment	$ 9,825,728	18,221,777
Other non-current assets	3,236,260	3,475,442
Total Assets	$ 504,929,035	446,847,092
Current Liabilities
Short-term bank loans, including current portion of long-term bank loans		57,902,600
Accounts payable	$ 14,997,591	4,829,350
Other payables and accrued expenses	46,997,452	49,692,757
Income tax payable	6,775,105	8,257,133
Total Current Liabilities	$ 68,770,148	120,681,840
Long-term bank loans, excluding current portion		40,000,000
Deferred income	$ 2,626,321	2,765,024
Other liabilities	8,086,775	8,138,498
Total Liabilities	79,483,244	171,585,362
Stockholders' Equity
Common stock: par value $0.0001; 100,000,000 shares authorized; 27,962,705 and 27,865,871 shares issued at June 30, 2015 and December 31, 2014, respectively; 25,708,001 and 24,806,167 shares outstanding at June 30, 2015 and December 31, 2014, respectively	2,797	2,787
Additional paid-in capital	89,462,086	24,008,281
Treasury stock: 2,254,704 and 3,059,704 shares at June 30, 2015 and December 31, 2014, respectively, at cost	(56,425,094)	(76,570,621)
Retained earnings	294,547,822	244,661,391
Accumulated other comprehensive income	20,318,850	19,985,189
Total equity attributable to China Biologic Products, Inc.	347,906,461	212,087,027
Noncontrolling interest	77,539,330	63,174,703
Total Stockholders' Equity	$ 425,445,791	$ 275,261,730
Commitments and contingencies
Total Liabilities and Stockholders' Equity	$ 504,929,035	$ 446,847,092

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Common Stock, Par Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	27,962,705	27,865,871
Common Stock, Shares, Outstanding	25,708,001	24,806,167
Treasury Stock, Shares	2,254,704	3,059,704

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Sales	$ 79,068,452	$ 60,073,984	$ 149,422,783	$ 116,340,561
Cost of sales	27,054,626	18,919,981	51,516,201	36,635,147
Gross profit	52,013,826	41,154,003	97,906,582	79,705,414
Operating expenses
Selling expenses	2,604,660	3,329,175	4,555,348	5,611,661
General and administrative expenses	8,121,390	7,112,798	15,974,585	14,329,424
Research and development expenses	1,046,985	1,838,795	2,389,307	2,912,361
Income from operations	40,240,791	28,873,235	74,987,342	56,851,968
Other income (expenses)
Equity in (loss) income of an equity method investee	(666,233)	1,523,216	(761,300)	1,860,579
Interest expense	(675,860)	(862,957)	(1,432,681)	(1,484,164)
Interest income	1,467,135	1,724,324	2,843,982	3,320,202
Total other income, net	125,042	2,384,583	650,001	3,696,617
Earnings before income tax expense	40,365,833	31,257,818	75,637,343	60,548,585
Income tax expense	6,123,661	4,486,157	11,739,811	9,824,375
Net income	34,242,172	26,771,661	63,897,532	50,724,210
Less: Net income attributable to noncontrolling interest	7,518,213	7,046,706	14,011,101	12,725,584
Net income attributable to China Biologic Products, Inc.	$ 26,723,959	$ 19,724,955	$ 49,886,431	$ 37,998,626
Net income per share of common stock:
Basic	$ 1.05	$ 0.83	$ 1.96	$ 1.55
Diluted	$ 0.99	$ 0.79	$ 1.86	$ 1.47
Weighted average shares used in computation:
Basic	25,019,039	23,483,090	24,918,517	24,212,766
Diluted	26,320,773	24,719,011	26,265,857	25,435,122
Net income	$ 34,242,172	$ 26,771,661	$ 63,897,532	$ 50,724,210
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	1,463,605	527,203	609,243	(2,589,440)
Comprehensive income	35,705,777	27,298,864	64,506,775	48,134,770
Less: Comprehensive income attributable to noncontrolling interest	7,831,571	7,140,585	14,286,683	12,245,986
Comprehensive income attributable to China Biologic Products, Inc.	$ 27,874,206	$ 20,158,279	$ 50,220,092	$ 35,888,784

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY - 6 months ended Jun. 30, 2015 - USD ($)	Total	Common stock [Member]	Additional paid-in capital [Member]	Retained earnings [Member]	Treasury Stock [Member]	Accumulated other comprehensive income [Member]	Equity attributable To China Biologic Products, Inc. [Member]	Noncontrolling interest [Member]
Balance at Dec. 31, 2014	$ 275,261,730	$ 2,787	$ 24,008,281	$ 244,661,391	$ (76,570,621)	$ 19,985,189	$ 212,087,027	$ 63,174,703
Balance (in shares) at Dec. 31, 2014		27,865,871
Net income	63,897,532			$ 49,886,431			49,886,431	14,011,101
Other comprehensive income	609,243					$ 333,661	333,661	$ 275,582
Share-based compensation	4,033,482		$ 4,033,482				4,033,482
Excess tax benefits from stock option exercises	288,681		210,737				210,737	$ 77,944
Common stock issued in connection with:
Exercise of stock options	$ 771,164	$ 9	771,155				$ 771,164
Exercise of stock options (in shares)		91,209
Vesting of restricted shares		$ 1	(1)
Vesting of restricted shares (in shares)		5,625
Reissuance of treasury stock	$ 80,583,959		60,438,432		$ 20,145,527		$ 80,583,959
Balance at Jun. 30, 2015	$ 425,445,791	$ 2,797	$ 89,462,086	$ 294,547,822	$ (56,425,094)	$ 20,318,850	$ 347,906,461	$ 77,539,330
Balance (in shares) at Jun. 30, 2015		27,962,705

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS	6 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 63,897,532	$ 50,724,210
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	4,123,599	3,289,535
Amortization	415,231	371,168
Loss on sale of property, plant and equipment and land use rights	313,529	71,494
Allowance for doubtful accounts - accounts receivable	35,372	$ 1,477
Allowance for doubtful accounts - other receivables and prepayments	796
Write-down of obsolete inventories	16,750	$ 9,092
Deferred tax expense	167,921	1,154,991
Share-based compensation	4,033,482	1,961,929
Equity in loss (income) of an equity method investee	761,300	(1,860,579)
Excess tax benefits from share-based compensation arrangements	(288,681)	(760,869)
Change in operating assets and liabilities:
Accounts receivable	(18,835,493)	(7,473,499)
Prepayment and other current assets	(1,165,997)	(2,393,459)
Inventories	(25,272,719)	(6,852,680)
Accounts payable	10,123,561	(438,427)
Other payables and accrued expenses	(2,391,597)	171,318
Deferred income	(149,708)	(74,721)
Income tax payable	(1,223,601)	1,126,281
Net cash provided by operating activities	34,561,277	39,027,261
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for property, plant and equipment	(16,486,212)	(10,243,198)
Payment for intangible assets and land use right	$ (4,205,678)	(1,227,914)
Refund of deposits related to land use right		1,635,200
Proceeds upon maturity of time deposit		6,608,612
Proceeds from sale of property, plant and equipment and land use rights	$ 559,029	190,660
Net cash used in investing activities	(20,132,861)	(3,036,640)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercised	771,164	1,643,559
Repayment of bank loans	$ (97,910,360)	(4,905,600)
Proceeds from long-term bank loans		$ 70,000,000
Maturity of deposit as security for short-term bank loan	$ 31,985,122
Payment for deposit as security for long-term bank loans		$ (72,290,922)
Payment for share repurchase		(70,000,000)
Excess tax benefits from share-based compensation arrangements	$ 288,681	760,869
Dividend paid by subsidiaries to noncontrolling interest shareholders		$ (1,409,542)
Net proceeds from reissuance of treasury stock	$ 80,583,959
Dividend to the trial court to be held in escrow as to dispute with Jie'an	(3,690,814)
Net cash provided by (used in) financing activities	12,027,752	$ (76,201,636)
EFFECTS OF FOREIGN EXCHANGE RATE CHANGE ON CASH	(661,684)	(703,847)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	25,794,484	(40,914,862)
Cash and cash equivalents at beginning of period	80,820,224	144,138,487
Cash and cash equivalents at end of period	106,614,708	103,223,625
Supplemental cash flow information
Cash paid for income taxes	12,829,660	7,564,408
Cash paid for interest expense	1,428,614	1,067,251
Noncash investing and financing activities:
Acquisition of property, plant and equipment included in payables	$ 231,397	$ 2,805,220

BASIS OF PRESENTATION, SIGNIFIC

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	6 Months Ended
	Jun. 30, 2015
BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS [Abstract]
BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	NOTE 1 – BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (a) Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2014 consolidated balance sheet was derived from the audited consolidated financial statements of China Biologic Products, Inc. (the “Company”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the December 31, 2014 audited consolidated financial statements of the Company included in the Company's annual report on Form 10-K for the year ended December 31, 2014. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2015, the results of operations for the three and six months ended June 30, 2015 and 2014, and cash flows for the six months ended June 30, 2015 and 2014, have been made. All significant intercompany transactions and balances are eliminated on consolidation. The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowance for doubtful accounts, the fair value determinations of equity instruments and stock compensation awards, the realizability of deferred tax assets and inventories, the recoverability of intangible assets, land use rights and property, plant and equipment, and accruals for income tax uncertainties and other contingencies. (b) Significant Concentration and Risks The Company's operations are carried out in the People's Republic of China (the “PRC”) and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, the Company's business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The Company's results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other matters. The Company maintains cash and deposit balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong or may exceed the insured limits for its bank accounts in China established by China Deposit Insurance Fund Management Institution. Total cash at banks and deposits as of June 30, 2015 and December 31, 2014 amounted to $ 178,482,788 184,186,306 2,952,780 86,744 The Company's two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 35.7 and 34.1 % of the total sales for the three months ended June 30, 2015 and 2014, respectively, and 36.9 % and 38.1 % of the total sales for the six months ended June 30, 2015 and 2014, respectively. IVIG accounted for 43.1 44.0 % of the total sales for the three months ended June 30, 2015 and 2014, and 44.8 % and 40.4 % of the total sales for the six months ended June 30, 2015 and 2014 , respectively. Substantially all of the Company's customers are located in the PRC. There were no customers that individually comprised 10% or more of the total sales during the three months and six months ended June 30, 2015 and June 30, 2014. There was one There were no suppliers that comprised 10% or more of the total purchases for the three months and six months ended June 30, 2015 and 2014, respectively. No vendors individually represented more than 10% of accounts payable at June 30, 2015 and December 31, 2014, respectively.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	6 Months Ended
	Jun. 30, 2015
ACCOUNTS RECEIVABLE [Abstract]
ACCOUNTS RECEIVABLE	NOTE 2 – ACCOUNTS RECEIVABLE Accounts receivable at June 30, 2015 and December 31, 2014 consisted of the following: June 30, 2015 December 31, 2014 USD USD Accounts receivable 38,800,023 19,836,768 Less: Allowance for doubtful accounts (471,192 ) (433,948 ) Total 38,328,831 19,402,820 The activity in the allowance for doubtful accounts for the six months ended June 30, 2015 and 2014 are as follows: For the six months ended June 30, 2015 June 30, 2014 USD USD Beginning balance 433,948 460,689 Provisions 35,372 1,477 Recoveries - - Write-offs - - Foreign currency translation adjustment 1,872 (3,380 ) Ending balance 471,192 458,786

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2015
INVENTORIES [Abstract]
INVENTORIES	NOTE 3 – INVENTORIES Inventories at June 30, 2015 and December 31, 2014 consisted of the following: June 30, 2015 December 31, 2014 USD USD Raw materials 64,953,705 52,010,104 Work-in-process 34,348,311 22,128,405 Finished goods 27,737,461 27,166,423 Total 127,039,477 101,304,932 An inventory write-down of $ 12,174 and nil An inventory write-down of $ 16,750 and $ 9,092 was recorded during the six months ended June 30, 2015 and 2014, respectively.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Jun. 30, 2015
PROPERTY, PLANT AND EQUIPMENT [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 4 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at June 30, 2015 and December 31, 2014 consisted of the following: June 30, 2015 December 31, 2014 USD USD Buildings 32,649,791 32,375,433 Machinery and equipment 61,107,253 58,946,498 Furniture, fixtures, office equipment and vehicles 8,637,938 8,230,842 Total property, plant and equipment, gross 102,394,982 99,552,773 Accumulated depreciation (34,365,280 ) (30,779,714 ) Total property, plant and equipment, net 68,029,702 68,773,059 Construction in progress 15,945,225 10,237,610 Prepayment for property, plant and equipment 7,233,506 1,220,219 Property, plant and equipment, net 91,208,433 80,230,888 Depreciation expense for the three months ended June 30, 2015 and 2014 was $ 1,922,579 1,817,138 4,123,599 3,289,535

DEPOSITS RELATED TO LAND USE RI

DEPOSITS RELATED TO LAND USE RIGHTS	6 Months Ended
	Jun. 30, 2015
DEPOSITS RELATED TO LAND USE RIGHTS [Abstract]
DEPOSITS RELATED TO LAND USE RIGHTS	NOTE 5 – DEPOSITS RELATED TO LAND USE RIGHTS In 2012, Guizhou Taibang made a refundable payment of RMB 83,400,000 13,641,738 23,000,000 3,762,110

RESTRICTED CASH DEPOSITS

RESTRICTED CASH DEPOSITS	6 Months Ended
	Jun. 30, 2015
RESTRICTED CASH DEPOSITS [Abstract]
RESTRICTED CASH DEPOSITS	NOTE 6 – RESTRICTED CASH DEPOSITS In February 2014, the Company made time deposits of RMB 246,500,000 40,320,005 194,600,000 31,830,722 40,000,000 30,000,000 two two In August 2014, the Company made a time deposit of RMB 196,300,000 32,108,791 194,000,000 31,732,580

BANK LOANS

BANK LOANS	6 Months Ended
	Jun. 30, 2015
BANK LOANS [Abstract]
BANK LOANS	NOTE 7 – BANK LOANS (a) Current The Company's bank loans as of June 30, 2015 and December 31, 2014 consisted of the following: Maturity Annual June 30, December 31, Loans date interest rate 2015 2014 USD USD Short-term bank loan, secured February 12, 2015 5.04 - 31,602,600 Current portion of long-term bank loans February 3, 2016 See note (b) - - Current portion of long-term bank loans August 11, 2015 See note (b) - 26,300,000 Total - 57,902,600 In August 2014, the Company entered into a credit facility agreement with CMB BJ Branch to finance the acquisition of additional equity interest in Guizhou Taibang. Pursuant to the facility agreement, the Company made a 6 194,000,000 31,732,580 196,300,000 32,108,791 Interest expense on short-term bank loans was nil and $ 73,213 for the three months ended June 30, 2015 and 2014, respectively. 191,609 205,957 The Company did not have any revolving line of credit at June 30, 2015. (b) Non-current June 30, 2015 December 31, 2014 USD USD Long-term bank loans - 66,300,000 Less: current portion of long-term bank loans - 26,300,000 Total non-current bank loans - 40,000,000 The Company entered into a credit facility agreement with CMB NY Branch in February, 2014 to finance the share repurchase. Pursuant to the facility agreement, CMB NY Branch lent to the Company a 24 40,000,000 18 30,000,000 246,500,000 40,320,005 194,600,000 31,830,722 1.2 3,700,000 two

INCOME TAX

INCOME TAX	6 Months Ended
	Jun. 30, 2015
INCOME TAX [Abstract]
INCOME TAX	NOTE 8 – INCOME TAX In October 2014, Shandong provincial government granted Shandong Taibang the High and New Technology Enterprise certificate. This certificate entitled Shandong Taibang to enjoy a preferential income tax rate of 15 According to Cai Shui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of PRC, enjoys a preferential income tax rate of 15 The Company's effective income tax rates were 15 % and 14 % for the three months ended June 30, 2015 and 2014. 16 16 As of and for the the three months ended June 30, 2015, the Company did not have any unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits to change significantly within the next 12 months.

OPTIONS AND NONVESTED SHARES

OPTIONS AND NONVESTED SHARES	6 Months Ended
	Jun. 30, 2015
OPTIONS AND NONVESTED SHARES [Abstract]
OPTIONS AND NONVESTED SHARES	NOTE 9 – OPTIONS AND NONVESTED SHARES Options A summary of stock options activity for the six months ended June 30, 2015 is as follow: Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Aggregate Intrinsic Value USD USD Outstanding at December 31, 2014 1,432,454 10.16 6.53 81,753,119 Granted - - Exercised (91,209 ) 8.45 7,942,509 Forfeited and expired - - Outstanding at June 30, 2015 1,341,245 10.27 6.21 140,678,176 Vested and expected to vest 1,341,245 10.27 6.21 140,678,176 Exercisable at June 30, 2015 1,098,745 10.37 6.00 115,140,501 For the three months ended June 30, 2015 and 2014, the Company recorded stock compensation expense of $ 337,789 and $ 427,447 , respectively, in general and administrative expenses. For the six months ended June 30, 2015 and 2014, the Company recorded stock compensation expense of $ 630,838 and $ 854,894 , respectively, in general and administrative expenses. At June 30, 2015, approximately $ 1,136,358 1.17 Nonvested shares A summary of nonvested shares activity for the six months ended June 30, 2015 is as follows: Number of Grant date weighted average fair value USD Outstanding at December 31, 2014 552,125 37.78 Granted 10,000 67.94 Vested (5,625 ) 18.58 Forfeited (7,500 ) 28.80 Outstanding at June 30, 2015 549,000 38.65 For the three months ended June 30, 2015 and 2014, the Company recorded stock compensation expense of $ 1,725,724 and $ 553,517 respectively in general and administrative expenses. For the six months ended June 30, 2015 and 2014, the Company recorded stock compensation expense of $ 3,402,644 and $ 1,107,035 respectively in general and administrative expenses. At June 30, 2015, approximately $ 15,547,156 2.52

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2015
FAIR VALUE MEASUREMENTS [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 10 – FAIR VALUE MEASUREMENTS Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates: • Short-term financial instruments (including cash and cash equivalents, restricted cash deposits, time deposits, accounts receivable, other receivables, short-term bank loans including current portion of long-term bank loans, accounts payable, and other payables and accrued expenses) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments. • Restricted cash and cash deposits, excluding current portion – The carrying amounts of the restricted cash and cash deposit approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company's incremental borrowing rates for similar borrowing. • Long-term bank loan excluding current portion– fair value is based on the amount of future cash flows associated with the long-term bank loan discounted at the Company's current borrowing rate for similar debt instruments of comparable terms. The carrying value of the long-term bank loan approximate its fair value as the long-term bank loan carry variable interest rate which approximate rate currently offered by the Company's bankers for similar debt instruments of comparable maturities.

SALES

SALES	6 Months Ended
	Jun. 30, 2015
SALES [Abstract]
SALES	NOTE 11 – SALES The Company's sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company's sales by significant types of product for the three months ended June 30, 2015 and 2014 are as follows: For the three months ended June 30, 2015 June 30, 2014 USD USD Human Albumin 28,202,452 20,490,892 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 34,075,251 26,446,025 Other Immunoglobulin products 6,650,652 4,993,559 Placenta Polypeptide 7,735,830 7,108,510 Others 2,404,267 1,034,998 Total 79,068,452 60,073,984 The Company's sales by significant types of product for the six months ended June 30, 2015 and 2014 are as follows: For the six months ended June 30, 2015 June 30, 2014 USD USD Human Albumin 55,095,482 44,271,893 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 66,941,041 46,975,796 Other Immunoglobulin products 10,984,774 13,276,807 Placenta Polypeptide 12,288,034 9,735,063 Others 4,113,452 2,081,002 Total 149,422,783 116,340,561

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2015
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 – COMMITMENTS AND CONTINGENCIES Capital commitments At June 30, 2015, commitments outstanding for the purchase of property, plant and equipment approximated $ 18,699,930 Legal proceedings Dispute with Jie'an over Certain Capital Injection into Guizhou Taibang In May 2007, a 91 20,000,000 9 50,960,000 8,335,527 21.4 1,800,000 20,000,000 50,960,000 8,335,527 6,480,000 1,059,933 In June 2007, Jie'an brought a lawsuit against Guizhou Taibang, alleging that it had a right to acquire the 18,200,000 18,200,000 During the second quarter of 2010, Jie'an requested that Guizhou Taibang register its 1.8 In December 2013, Jie'an brought a third lawsuit against Guizhou Taibang, requesting Guizhou Taibang to register 1.8 13,809,197 2,258,770 1.8 18,339,227 2,999,747 22,639,227 3,703,098 Guizhou Taibang appealed to the High Court of Guizhou, which accepted our appeal and stayed the enforcement procedures at the trial court in June 2015. In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the November 2013 Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie'an's request that Jie'an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 In March 2014, Guizhou Taibang held another shareholders meeting and the shareholders passed resolutions, or the March 2014 Resolutions, that, inter alia If the pending cases with Jie'an are ultimately ruled in Jie'an's favor, the ownership interest in Guizhou Taibang may be diluted to 71 5,040,000 824,393 1,440,000 235,541 3,519,608 575,702 Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang In part due to the invalidity of the Equity Purchase Agreement with certain alleged strategic investors in May 2007, which was never approved or ratified by Guizhou Taibang's shareholders, such investors' equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have never been registered with the local AIC. In January 2010, one individual among such investors brought a lawsuit against Guizhou Taibang requesting to register his 14.35 In October 2010, the trial court denied such individual investor's right as shareholders of Guizhou Taibang and his entitlement to share the dividends, which ruling was reaffirmed after a re-trial by the same trial court in December 2012. After such ruling, Guizhou Taibang attempted to return the originally received fund of RMB 34,160,000 5,587,551 11,200,000 1,831,984 As of June 30, 2015, Guizhou Taibang had maintained, on its balance sheet, payables to the investors of RMB 34,160,000 5,587,551 16,818,175 2,750,948 341,600 55,876 1

NET INCOME PER SHARE

NET INCOME PER SHARE	6 Months Ended
	Jun. 30, 2015
NET INCOME PER SHARE [Abstract]
NET INCOME PER SHARE	NOTE 13 – NET INCOME PER SHARE The following table sets forth the computation of basic and diluted net income per share for the periods indicated: For the three months ended June 30, 2015 June 30, 2014 USD USD Net income attributable to China Biologic Products, Inc. 26,723,959 19,724,955 Earnings allocated to participating nonvested shares (573,820 ) (295,479 ) Net income used in basic/diluted net income per common stock 26,150,139 19,429,476 Weighted average shares used in computing basic net income per common stock 25,019,039 23,483,090 Diluted effect of stock option 1,301,734 1,235,921 Weighted average shares used in computing diluted net income per common stock 26,320,773 24,719,011 Net income per common stock – basic 1.05 0.83 Net income per common stock – diluted 0.99 0.79 During the three months ended June 30, 2015 and 2014, no option was antidilutive or excluded from the calculation of diluted net income per common stock. The following table sets forth the computation of basic and diluted net income per share for the periods indicated: For the six months ended June 30, 2015 June 30, 2014 USD USD Net income attributable to China Biologic Products, Inc. 49,886,431 37,998,626 Earnings allocated to participating nonvested shares (1,076,448 ) (554,349 ) Net income used in basic/diluted net income per common stock 48,809,983 37,444,277 Weighted average shares used in computing basic net income per common stock 24,918,517 24,212,766 Diluted effect of stock option 1,347,340 1,222,356 Weighted average shares used in computing diluted net income per common stock 26,265,857 25,435,122 Net income per common stock – basic 1.96 1.55 Net income per common stock – diluted 1.86 1.47 During the six months ended June 30, 2015 and 2014, no option was antidilutive or excluded from the calculation of diluted net income per common stock.

FOLLOW-ON OFFERING OF COMMON ST

FOLLOW-ON OFFERING OF COMMON STOCK	6 Months Ended
	Jun. 30, 2015
FOLLOW-ON OFFERING OF COMMON STOCK [Abstract]
FOLLOW-ON OFFERING OF COMMON STOCK	NOTE 14 – FOLLOW-ON OFFERING OF COMMON STOCK On June 15, 2015, the Company completed a follow-on offering of 3,450,000 105.00 805,000 105,000 2,645,000 345,000 80.6

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	6 Months Ended
	Jun. 30, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
SCHEDULE OF ACCOUNTS RECEIVABLE	June 30, 2015 December 31, 2014 USD USD Accounts receivable 38,800,023 19,836,768 Less: Allowance for doubtful accounts (471,192 ) (433,948 ) Total 38,328,831 19,402,820
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	For the six months ended June 30, 2015 June 30, 2014 USD USD Beginning balance 433,948 460,689 Provisions 35,372 1,477 Recoveries - - Write-offs - - Foreign currency translation adjustment 1,872 (3,380 ) Ending balance 471,192 458,786

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2015
INVENTORIES [Abstract]
SCHEDULE OF INVENTORIES	June 30, 2015 December 31, 2014 USD USD Raw materials 64,953,705 52,010,104 Work-in-process 34,348,311 22,128,405 Finished goods 27,737,461 27,166,423 Total 127,039,477 101,304,932

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2015
PROPERTY, PLANT AND EQUIPMENT [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	June 30, 2015 December 31, 2014 USD USD Buildings 32,649,791 32,375,433 Machinery and equipment 61,107,253 58,946,498 Furniture, fixtures, office equipment and vehicles 8,637,938 8,230,842 Total property, plant and equipment, gross 102,394,982 99,552,773 Accumulated depreciation (34,365,280 ) (30,779,714 ) Total property, plant and equipment, net 68,029,702 68,773,059 Construction in progress 15,945,225 10,237,610 Prepayment for property, plant and equipment 7,233,506 1,220,219 Property, plant and equipment, net 91,208,433 80,230,888

BANK LOANS (Tables)

BANK LOANS (Tables)	6 Months Ended
	Jun. 30, 2015
BANK LOANS [Abstract]
SCHEDULE OF SHORT-TERM BANK LOANS	Maturity Annual June 30, December 31, Loans date interest rate 2015 2014 USD USD Short-term bank loan, secured February 12, 2015 5.04 - 31,602,600 Current portion of long-term bank loans February 3, 2016 See note (b) - - Current portion of long-term bank loans August 11, 2015 See note (b) - 26,300,000 Total - 57,902,600
SCHDULE OF NON-CURRENT LONG TERM BANK LOANS	June 30, 2015 December 31, 2014 USD USD Long-term bank loans - 66,300,000 Less: current portion of long-term bank loans - 26,300,000 Total non-current bank loans - 40,000,000

OPTIONS AND NONVESTED SHARES (T

OPTIONS AND NONVESTED SHARES (Tables)	6 Months Ended
	Jun. 30, 2015
OPTIONS AND NONVESTED SHARES [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Aggregate Intrinsic Value USD USD Outstanding at December 31, 2014 1,432,454 10.16 6.53 81,753,119 Granted - - Exercised (91,209 ) 8.45 7,942,509 Forfeited and expired - - Outstanding at June 30, 2015 1,341,245 10.27 6.21 140,678,176 Vested and expected to vest 1,341,245 10.27 6.21 140,678,176 Exercisable at June 30, 2015 1,098,745 10.37 6.00 115,140,501
SCHEDULE OF NONVESTED SHARES ACTIVITY	Number of Grant date weighted average fair value USD Outstanding at December 31, 2014 552,125 37.78 Granted 10,000 67.94 Vested (5,625 ) 18.58 Forfeited (7,500 ) 28.80 Outstanding at June 30, 2015 549,000 38.65

SALES (Tables)

SALES (Tables)	6 Months Ended
	Jun. 30, 2015
SALES [Abstract]
SCHEDULE OF SALES BY PRODUCT TYPE	For the three months ended June 30, 2015 June 30, 2014 USD USD Human Albumin 28,202,452 20,490,892 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 34,075,251 26,446,025 Other Immunoglobulin products 6,650,652 4,993,559 Placenta Polypeptide 7,735,830 7,108,510 Others 2,404,267 1,034,998 Total 79,068,452 60,073,984 For the six months ended June 30, 2015 June 30, 2014 USD USD Human Albumin 55,095,482 44,271,893 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 66,941,041 46,975,796 Other Immunoglobulin products 10,984,774 13,276,807 Placenta Polypeptide 12,288,034 9,735,063 Others 4,113,452 2,081,002 Total 149,422,783 116,340,561

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2015
NET INCOME PER SHARE [Abstract]
SCHEDULE OF EPS - BASIC AND DILUTED	For the three months ended June 30, 2015 June 30, 2014 USD USD Net income attributable to China Biologic Products, Inc. 26,723,959 19,724,955 Earnings allocated to participating nonvested shares (573,820 ) (295,479 ) Net income used in basic/diluted net income per common stock 26,150,139 19,429,476 Weighted average shares used in computing basic net income per common stock 25,019,039 23,483,090 Diluted effect of stock option 1,301,734 1,235,921 Weighted average shares used in computing diluted net income per common stock 26,320,773 24,719,011 Net income per common stock – basic 1.05 0.83 Net income per common stock – diluted 0.99 0.79 For the six months ended June 30, 2015 June 30, 2014 USD USD Net income attributable to China Biologic Products, Inc. 49,886,431 37,998,626 Earnings allocated to participating nonvested shares (1,076,448 ) (554,349 ) Net income used in basic/diluted net income per common stock 48,809,983 37,444,277 Weighted average shares used in computing basic net income per common stock 24,918,517 24,212,766 Diluted effect of stock option 1,347,340 1,222,356 Weighted average shares used in computing diluted net income per common stock 26,265,857 25,435,122 Net income per common stock – basic 1.96 1.55 Net income per common stock – diluted 1.86 1.47

BASIS OF PRESENTATION, SIGNIF28

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2015USD ($)item	Jun. 30, 2014item	Jun. 30, 2015USD ($)item	Jun. 30, 2014item	Dec. 31, 2014USD ($)item
Basis Of Presentation Significant Concentration And Risk [Line Items]
Total cash at banks and deposits including insured amount | $	$ 178,482,788		$ 178,482,788		$ 184,186,306
Cash, Insured Amount | $	$ 2,952,780		$ 2,952,780		$ 86,744
Customers represented 10% or more of accounts receivables	1		1		0
Customers that individually comprised 10% or more of the total sales	0	0	0	0
Suppliers that comprised 10% or more of the total purchases	0	0	0	0
Suppliers that represented more than 10% of accounts payables	0		0		0
Human Albumin [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	35.70%	34.10%	36.90%	38.10%
Human Immunoglobulin For Intravenous Injection [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	43.10%	44.00%	44.80%	40.40%

ACCOUNTS RECEIVABLE (Schedule O

ACCOUNTS RECEIVABLE (Schedule Of Accounts Receivable) (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 38,800,023	$ 19,836,768
Less: Allowance for doubtful accounts	(471,192)	(433,948)
Total	$ 38,328,831	$ 19,402,820

ACCOUNTS RECEIVABLE (Schedule30

ACCOUNTS RECEIVABLE (Schedule Of Activity In Allowance For Doubtful Accounts) (Details) - Accounts Receivable [Member] - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 433,948	$ 460,689
Provisions	$ 35,372	$ 1,477
Recoveries
Write-offs
Foreign currency translation adjustment	$ 1,872	$ (3,380)
Ending balance	$ 471,192	$ 458,786

INVENTORIES (Schedule Of Invent

INVENTORIES (Schedule Of Inventories) (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 64,953,705	$ 52,010,104
Work-in-process	34,348,311	22,128,405
Finished goods	27,737,461	27,166,423
Total	$ 127,039,477	$ 101,304,932

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Write-down of obsolete inventories	$ 12,174		$ 16,750	$ 9,092

PROPERTY, PLANT AND EQUIPMENT33

PROPERTY, PLANT AND EQUIPMENT (Schedule Of Property Plant And Equipment)(Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 102,394,982	$ 99,552,773
Accumulated depreciation	(34,365,280)	(30,779,714)
Total property, plant and equipment, net	68,029,702	68,773,059
Construction in progress	15,945,225	10,237,610
Prepayment for property, plant and equipment	7,233,506	1,220,219
Property, plant and equipment, net	91,208,433	80,230,888
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	32,649,791	32,375,433
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	61,107,253	58,946,498
Furniture, Fixtures, Office Equipment and Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 8,637,938	$ 8,230,842

PROPERTY, PLANT AND EQUIPMENT34

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Depreciation	$ 1,922,579	$ 1,817,138	$ 4,123,599	$ 3,289,535

DEPOSITS RELATED TO LAND USE 35

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	6 Months Ended		12 Months Ended		42 Months Ended
	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)	Jun. 30, 2015USD ($)	Jun. 30, 2015CNY (¥)
DEPOSITS RELATED TO LAND USE RIGHTS [Abstract]
Payment for refundable deposits			$ 13,641,738	¥ 83,400,000
Refund of deposits related to land use right		$ 1,635,200			$ 3,762,110	¥ 23,000,000

RESTRICTED CASH DEPOSITS (Narra

RESTRICTED CASH DEPOSITS (Narrative) (Details) - Secured Debt [Member]	1 Months Ended				6 Months Ended
	Aug. 31, 2014USD ($)	Aug. 31, 2014CNY (¥)	Feb. 28, 2014USD ($)	Feb. 28, 2014CNY (¥)	Jun. 30, 2015USD ($)	Jun. 30, 2015CNY (¥)
CMB BJ Branch [Member] | Short Term Bank Loan One [Member]
Restricted Cash Deposits [Line items]
Payment made for time deposits secured for loans	$ 32,108,791	¥ 196,300,000
Bank loans, face amount					$ 31,732,580	¥ 194,000,000
Bank loans, term					6 months
Time deposit, maturity date					2015-02
Bank loans, fully repaid date					2015-02
CMB BJ Branch [Member] | Long Term Bank Loan One [Member]
Restricted Cash Deposits [Line items]
Payment made for time deposits secured for loans			$ 40,320,005	¥ 246,500,000
CMB BJ Branch [Member] | Long Term Bank Loan Two [Member]
Restricted Cash Deposits [Line items]
Payment made for time deposits secured for loans			$ 31,830,722	¥ 194,600,000
CMB NY Branch [Member] | Long Term Bank Loan One [Member]
Restricted Cash Deposits [Line items]
Bank loans, face amount					$ 40,000,000
Bank loans, term					24 months
Time deposit, maturity date					2015-06
Bank loans, fully repaid date					2015-06
CMB NY Branch [Member] | Long Term Bank Loan Two [Member]
Restricted Cash Deposits [Line items]
Bank loans, face amount					$ 30,000,000
Bank loans, term					18 months
Time deposit, maturity date					2015-06
Bank loans, fully repaid date					2015-06

BANK LOANS (Schedule Of Current

BANK LOANS (Schedule Of Current Bank Loans) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Short-term Debt [Line Items]
Current portion of long-term bank loans		$ 26,300,000
Total		57,902,600
Secured Debt [Member] | Short Term Bank Loan One [Member]
Short-term Debt [Line Items]
Maturity date	Feb. 12, 2015
Annual interest rate	5.04%
Short-term bank loan		$ 31,602,600
Secured Debt [Member] | Long Term Bank Loan One [Member]
Short-term Debt [Line Items]
Maturity date	Feb. 3, 2016
Current portion of long-term bank loans
Secured Debt [Member] | Long Term Bank Loan Two [Member]
Short-term Debt [Line Items]
Maturity date	Aug. 11, 2015
Current portion of long-term bank loans		$ 26,300,000

BANK LOANS (Schedule Of Non-cur

BANK LOANS (Schedule Of Non-current Bank Loans) (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term bank loans		$ 66,300,000
Less: current portion of long-term bank loans		26,300,000
Total non-current bank loans		$ 40,000,000

BANK LOANS (Narrative) (Details

BANK LOANS (Narrative) (Details) - Secured Debt [Member]	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2015CNY (¥)
CMB BJ Branch [Member] | Short Term Bank Loan One [Member]
Credit facility agreement, bank loans [Line items]
Bank loans, issuance date				2014-08
Bank loans, face amount		$ 31,732,580		$ 31,732,580		¥ 194,000,000
Bank loans, term				6 months
Bank loans, collateral amount		$ 32,108,791		$ 32,108,791		196,300,000
Bank loans, collateral description				time deposit
Short term bank loan, interest expense			$ 73,213	$ 191,609	$ 205,957
Bank loans, fully repaid date				2015-02
CMB NY Branch [Member] | Long Term Bank Loan One [Member]
Credit facility agreement, bank loans [Line items]
Bank loans, issuance date				2014-02
Bank loans, face amount		$ 40,000,000		$ 40,000,000
Bank loans, term				24 months
Bank loans, collateral amount		40,320,005		$ 40,320,005		246,500,000
Bank loans, collateral description				time deposit
Bank loans, fully repaid date				2015-06
Credit facility, interest rate description				3-month LIBOR plus 1.3% per annum
Credit facility, facility fee				1.20%
CMB NY Branch [Member] | Long Term Bank Loan Two [Member]
Credit facility agreement, bank loans [Line items]
Bank loans, issuance date				2014-02
Bank loans, face amount		30,000,000		$ 30,000,000
Bank loans, term				18 months
Bank loans, collateral amount		$ 31,830,722		$ 31,830,722		¥ 194,600,000
Bank loans, collateral description				time deposit
Bank loans, repayment	$ 3,700,000
Bank loans, fully repaid date				2015-06
Credit facility, interest rate description				3-month LIBOR plus 1.3% per annum
Credit facility, facility fee				1.20%

INCOME TAX (Narrative) (Details

INCOME TAX (Narrative) (Details)	3 Months Ended		6 Months Ended		36 Months Ended	120 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2016	Dec. 31, 2020
INCOME TAX [Line Items]
Effective income tax rate	15.00%	14.00%	16.00%	16.00%
Shandong Taibang [Member] | Scenario, Forecast [Member]
INCOME TAX [Line Items]
Preferential income tax rate					15.00%
Guizhou Taibang [Member] | Scenario, Forecast [Member]
INCOME TAX [Line Items]
Preferential income tax rate						15.00%

OPTIONS AND NONVESTED SHARES (S

OPTIONS AND NONVESTED SHARES (Schedule Of Stock Options Activity) (Details) - Stock Option [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at beginning	1,432,454
Number of Options, Granted
Number of Options, Exercised	(91,209)
Number of Options, Forfeited and expired
Number of Options, Outstanding	1,341,245	1,432,454
Number of Options, Vested and expected to vest	1,341,245
Number of Options, Exercisable	1,098,745
Weighted Average Exercise Price, Outstanding at beginning	$ 10.16
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised	$ 8.45
Weighted Average Exercise Price, Forfeited and expired
Weighted Average Exercise Price, Outstanding	$ 10.27	$ 10.16
Weighted Average Exercise Price, Vested and expected to vest	10.27
Weighted Average Exercise Price, Exercisable	$ 10.37
Weighted Average Remaining Contractual Term in Years, Outstanding	6 years 2 months 16 days	6 years 6 months 11 days
Weighted Average Remaining Contractual Term in Years, Vested and expected to vest	6 years 2 months 16 days
Weighted Average Remaining Contractual Term in Years, Exercisable	6 years
Aggregate Intrinsic Value, Outstanding at beginning	$ 81,753,119
Aggregate Intrinsic Value, Exercised	7,942,509
Aggregate Intrinsic Value, Outstanding	140,678,176	$ 81,753,119
Aggregate Intrinsic Value Vested and expected to vest	140,678,176
Aggregate Intrinsic Value, Exercisable	$ 115,140,501

OPTIONS AND NONVESTED SHARES 42

OPTIONS AND NONVESTED SHARES (Schedule Of Nonvested Shares Activity) (Details) - 6 months ended Jun. 30, 2015 - Non Vested Shares [Member] - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of nonvested shares, Outstanding	552,125
Number of nonvested shares, Granted	10,000
Number of nonvested shares, Vested	(5,625)
Number of nonvested shares, Forfeited	(7,500)
Number of nonvested shares, Outstanding	549,000
Grant date weighted average fair value, Outstanding	$ 37.78
Grant date weighted average fair value, Granted	67.94
Grant date weighted average fair value, Vested	18.58
Grant date weighted average fair value, Forfeited	28.80
Grant date weighted average fair value, Outstanding	$ 38.65

OPTIONS AND NONVESTED SHARES (N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Warrants and Options Disclosure [Line Items]
Stock compensation expense related to options	$ 337,789	$ 427,447	$ 630,838	$ 854,894
Stock compensation expense with respect to non-vested stock option	1,136,358		$ 1,136,358
Stock compensation expense to be recognized with respect to non-vested stock option			1 year 2 months 1 day
Stock compensation expense related to nonvested shares	1,725,724	$ 553,517	$ 3,402,644	$ 1,107,035
Stock compensation expense to be recognized with respect to non-vested shares	$ 15,547,156		$ 15,547,156
Stock compensation expense with respect to non-vested shares weighted average vesting period			2 years 6 months 7 days

SALES (Schedule Of Sales By Sig

SALES (Schedule Of Sales By Significant Types Of Product) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Immunoglobulin products:
Sales	$ 79,068,452	$ 60,073,984	$ 149,422,783	$ 116,340,561
Human Albumin [Member]
Immunoglobulin products:
Sales	28,202,452	20,490,892	55,095,482	44,271,893
Human Immunoglobulin For Intravenous Injection [Member]
Immunoglobulin products:
Sales	34,075,251	26,446,025	66,941,041	46,975,796
Other Immunoglobulin Products [Member]
Immunoglobulin products:
Sales	6,650,652	4,993,559	10,984,774	13,276,807
Placenta Polypeptide [Member]
Immunoglobulin products:
Sales	7,735,830	7,108,510	12,288,034	9,735,063
Others [Member]
Immunoglobulin products:
Sales	$ 2,404,267	$ 1,034,998	$ 4,113,452	$ 2,081,002

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	1 Months Ended								3 Months Ended			6 Months Ended			12 Months Ended
	Jul. 31, 2014USD ($)	Jul. 31, 2014CNY (¥)	Nov. 30, 2010USD ($)	Nov. 30, 2010CNY (¥)	Oct. 31, 2010USD ($)	Oct. 31, 2010CNY (¥)	May. 31, 2009shares	May. 31, 2007USD ($)shares	Jun. 30, 2015USD ($)	Jun. 30, 2014USD ($)	Jun. 30, 2010shares	Jun. 30, 2015USD ($)shares	Jun. 30, 2015CNY (¥)shares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)shares	Dec. 31, 2014CNY (¥)shares	Dec. 31, 2013shares	Jun. 30, 2015CNY (¥)	Nov. 30, 2013shares	Jan. 31, 2010	Jun. 30, 2007shares	May. 31, 2007CNY (¥)shares
Loss Contingencies [Line Items]
Capital commitment, amount committed | $									$ 18,699,930			$ 18,699,930
Denied the rights of first refusal of Jie'an over the 18,200,000 shares							18,200,000
Interest Expense | $									675,860	$ 862,957		$ 1,432,681		$ 1,484,164
Alleged Right to acquire common stock shares in a lawsuit																					18,200,000
Dispute with Jie'an over Certain Capital Injection into Guizhou Taibang [Member]
Loss Contingencies [Line Items]
91% controlling interest of Guizhou Taibang's shareholders								91.00%														91.00%
Issuance of an additional 20,000,000 shares of Guizhou Taibang								20,000,000
Remaining 9% noncontrolling interest								9.00%														9.00%
Investors agreed to invest								$ 8,335,527														¥ 50,960,000
21.4%, of Guizhou Taibang's equity interests								21.40%														21.40%
Subscribed for 1,800,000 shares								1,800,000														1,800,000
Share of the 20,000,000 shares being offered								20,000,000														20,000,000
Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC											1,800,000						1,800,000
The appellate court ruled in favor of Jie'an supporting its request to register 1.8 million shares															1,800,000	1,800,000
Diluted to 71%												71.00%	71.00%
Jie'an may be entitled to receive accumulated dividends and the related interest expenses												$ 2,985,810	¥ 18,339,227
Jie'an claimed share of Guizhou Taibang's accumulated dividend distributions associated with the 1.8 million shares												1,800,000	1,800,000
Payables to Jie an for the additional funds received									824,393			$ 824,393						¥ 5,040,000
Payables to Jie an for over-paid subscription									235,541			235,541						1,440,000
Payable to Jie an for the accrued interest									$ 575,702			575,702						¥ 3,519,608
Common Stock, Capital Shares Reserved for Future Issuance																			20,000,000
Payment to trial court held in escrow												3,703,098	¥ 22,639,227
The appellate court ordered Guizhou Taibang to pay Jie'an its share of accumulated dividends associated with these shares plus the related interest expenses															$ 2,999,747	¥ 18,339,227
Guizhou Taibang to pay accumulated dividends associated with these shares and the related interest expenses to Jie'an	$ 2,258,770	¥ 13,809,197
Jiean [Member]
Loss Contingencies [Line Items]
Investors agreed to invest								$ 1,059,933														¥ 6,480,000
Investor [Member]
Loss Contingencies [Line Items]
Investors agreed to invest								$ 8,335,527														¥ 50,960,000
Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang [Member]
Loss Contingencies [Line Items]
Another investor accepted the returned fund			$ 1,831,984	¥ 11,200,000
Penalty												$ 55,876	¥ 341,600
Penalty Imposed By The Agreement												1.00%	1.00%
Interest Expense												$ 2,750,948	¥ 16,818,175
Originally Return Amount					$ 5,587,551	¥ 34,160,000
Equity Method Investment, Ownership Percentage																				14.35%
Originally Received Funds												$ 5,587,551	¥ 34,160,000

NET INCOME PER SHARE - (Schedul

NET INCOME PER SHARE - (Schedule Of Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Net income attributable to China Biologic Products, Inc.	$ 26,723,959	$ 19,724,955	$ 49,886,431	$ 37,998,626
Earnings allocated to participating nonvested shares	(573,820)	(295,479)	(1,076,448)	(554,349)
Net income used in basic/diluted net income per common stock	$ 26,150,139	$ 19,429,476	$ 48,809,983	$ 37,444,277
Weighted average shares used in computing basic net income per common stock	25,019,039	23,483,090	24,918,517	24,212,766
Diluted effect of stock option	1,301,734	1,235,921	1,347,340	1,222,356
Weighted average shares used in computing diluted net income per common stock	26,320,773	24,719,011	26,265,857	25,435,122
Net income per common stock - basic	$ 1.05	$ 0.83	$ 1.96	$ 1.55
Net income per common stock - diluted	$ 0.99	$ 0.79	$ 1.86	$ 1.47

FOLLOW-ON OFFERING OF COMMON 47

FOLLOW-ON OFFERING OF COMMON STOCK (Narrative) (Details) - Jun. 15, 2015 - USD ($) $ / shares in Units, $ in Millions	Total
FOLLOW-ON OFFERING OF COMMON STOCK [Line Items]
Shares sold	3,450,000
Price per share of shares of common stock sold	$ 105
Net proceeds from offering	$ 80.6
Shares sold by the Company	805,000
Shares sold by certain selling stockholders	2,645,000
Underwriters option to purchase additional shares [Member]
FOLLOW-ON OFFERING OF COMMON STOCK [Line Items]
Shares sold by the Company	105,000
Shares sold by certain selling stockholders	345,000